Vivos Therapeutics, Inc. Cash Flow Statement
VVOS|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Vivos Therapeutics, Inc. used $13M in operating cash flow and negative free cash flow of $13M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M |
| Depreciation & Amortization | $581.0K | $621.0K | $669.0K | $733.0K | $718.0K | $751.2K |
| Operating Cash Flow | -$12.7M | -$11.9M | -$19.6M | -$15.7M | -$5.7M | -$5.3M |
| Capital Expenditures | $568.0K | $803.0K | $924.0K | $2.4M | $120.0K | $175.6K |
| Free Cash Flow | -$13.3M | -$12.7M | -$20.5M | -$18.1M | -$5.8M | -$5.5M |
| FCF Margin | -88.2% | -92.4% | -128.0% | -107.4% | -44.4% | -48.4% |